tiprankstipranks
Company Announcements

Shanghai Bio-heart’s Iberis® RDN System Gains NMPA Approval

Story Highlights
  • Shanghai Bio-heart focuses on medical technology, offering the Iberis® RDN system for hypertension.
  • The Iberis® RDN system received NMPA approval, enhancing the company’s market position.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Shanghai Bio-heart’s Iberis® RDN System Gains NMPA Approval

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) has issued an update.

Shanghai Bio-heart Biological Technology Co., Ltd. announced that its Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System has received approval from China’s National Medical Products Administration for treating resistant hypertension and hypertension patients with drug intolerance. This approval marks a significant milestone for the company, enhancing its market position and potentially impacting stakeholders positively. The Iberis-HTN trial demonstrated the system’s efficacy and safety, showing significant improvements in blood pressure management compared to control groups.

More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H

Shanghai Bio-heart Biological Technology Co., Ltd. operates in the biotechnology industry, focusing on the development of medical technology solutions. The company’s primary product is the Iberis® RDN system, which is designed for the treatment of resistant hypertension and hypertension patients with drug intolerance. The company aims to advance its position in the medical technology market through innovative solutions.

YTD Price Performance: 5.49%

Average Trading Volume: 56,982

Technical Sentiment Consensus Rating: Buy

Current Market Cap: HK$724.1M

For detailed information about 2185 stock, go to TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App